Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Recruitment status was: Recruiting
Drug: bevacizumab combined with dose dense chemotherapy
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymp Node Positive Breast Cancer: A Pilot Study|
- Incidence of treatment failure, 2 and 5 year Disease Free Survival.
- 2 and 5 Year Disease Free Survival.
- Overall survival.
- Circulating Tumor Cells and Circulating Endothelial Progenitor Cells assays results and their association with clinical outcomes.
- Toxicities and adverse events.
|Study Start Date:||June 2006|
|Estimated Study Completion Date:||October 2008|
Approximately 200,000 women are diagnosed with breast cancer in the United States every year. A significant factor determining long-term survivability of breast cancer is whether or not lymph nodes, glands which cleanse and filter the body's fluids, are involved. Despite treatment with approved multiagent cytotoxic chemotherapy ("dose-dense chemotherapy"), women with breast cancer involving more than 4 axillary lymph nodes still have a high risk for recurrence.
Several dose-dense chemotherapy regimens are currently being compared in other studies, however, at this time there is no proof that one regimen is superior to another. Therefore, in an attempt to decrease metastases, prolong time to recurrence and improve overall survival, it is essential to develop novel therapeutic strategies. The use of inhibitors of angiogenesis represents a promising option.
Bevacizumab is the first angiogenesis inhibiting drug to be FDA approved, for the treatment of colon cancer. It is has also been studied alone in progressed lymph-node positive breast cancer and has shown moderate efficacy.
This study will observe the efficacy and tolerability of using bevacizumab in combination with an approved dose-dense chemotherapy regimen for 8 cycles, followed by 12 of bevacizumab alone. Patients may be on the study for up to 52 weeks if their disease has not progressed and the regimen is tolerated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00378638
|Contact: Linnea I. Chap, MD||(310) email@example.com|
|Contact: Marilyn Mulay, MSN||(310) firstname.lastname@example.org|
|United States, California|
|Santa Monica, California, United States, 90404|
|Contact: Linnea I. Chap, M.D. 310-633-8400 email@example.com|
|Contact: Marilyn Mulay, MSN (310) 633-8400 firstname.lastname@example.org|
|Principal Investigator: Linnea I. Chap, M.D.|
|Principal Investigator:||Linnea I. Chap, MD||Premiere Oncology, A Medical Corporation|